ATH 0.00% 0.3¢ alterity therapeutics limited

ACS Infect Dis. 2019 Nov 11. doi: 10.1021/acsinfecdis.9b00307....

  1. 2,862 Posts.
    lightbulb Created with Sketch. 1000
    ACS Infect Dis. 2019 Nov 11. doi: 10.1021/acsinfecdis.9b00307. [Epub ahead of print]

    Neisseria gonorrhoeae Becomes Susceptible to Polymyxin B and Colistin in the Presence of PBT2.

    Author information

    1
    Institute for Glycomics , Griffith University , Gold Coast Campus , Southport , Queensland 4222 , Australia.
    2
    School of Chemistry and Molecular Biosciences and Australian Infectious Diseases Research Centre , The University of Queensland , Brisbane , Queensland 4072 , Australia.

    Abstract

    Neisseria gonorrhoeae (N. gonorrhoeae) causes the sexually transmitted disease gonorrhea, which has a global incidence of 106 million cases per year. No vaccine is available to prevent the disease, and the emergence of multidrug resistant (MDR) strains makes N. gonorrhoeae an immediate public health threat. Here, we show that an ionophore, PBT2, can reverse the intrinsic resistance of N. gonorrhoeae to polymyxin B and colistin. These antibiotics administered in combination with PBT2 may be an effective path to treat MDR gonococcal infections.


 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
0.000(0.00%)
Mkt cap ! $15.96M
Open High Low Value Volume
0.3¢ 0.3¢ 0.3¢ $6.025K 2.008M

Buyers (Bids)

No. Vol. Price($)
76 110094686 0.2¢
 

Sellers (Offers)

Price($) Vol. No.
0.3¢ 33830719 2
View Market Depth
Last trade - 14.27pm 11/11/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.